Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance—protocol for a systematic review by Frank Kunath et al.
PROTOCOL Open Access
Prognostic factors for tumor recurrence in
patients with clinical stage I seminoma
undergoing surveillance—protocol for a
systematic review
Frank Kunath1,5*, Annabel Spek2,5, Katrin Jensen3, Friedemann Zengerling4,5† and Stefanie Schmidt5†
Abstract
Background: Testicular cancer is primarily treated with the surgical removal of the affected testis. About 50 % of
testicular cancer patients present with a stage I seminoma. If no chemo- or radiotherapy as adjuvant treatment is
initiated after orchiectomy, 15–20 % of these patients will develop metastases. Although adjuvant treatment is
effective in reducing the relapse risk, there is rising concern about overtreatment of these patients. Prognostic
factors at primary diagnosis might have the potential to identify patients at higher risk of tumor relapse, allowing to
guide individual therapy and to avoid overtreatment. Therefore, we aim to synthesize the available evidence on
tumor or patient characteristics as possible prognostic factors for cancer recurrence in patients with clinical stage I
seminoma.
Methods/design: We will conduct a broad systematic review to analyze what prognostic factors predict cancer
recurrence in patients with a first time diagnosis of clinical stage I seminoma, who received no adjuvant chemo- or
radiotherapy after orchiectomy. The literature search will comprise MEDLINE, Web of Science, the Cochrane Central
Register of Controlled Trials (CENTRAL), and the conference proceedings of the American Society of Clinical
Oncology (ASCO), American Urologic Association (AUA), and European Urologic Association (EAU) Annual Meetings.
Prospective and retrospective longitudinal studies reporting on prognostic factors for cancer recurrence will be
considered. We will consider the wealth of any candidate clinical or pathological prognostic factor reported in the
literature. Our outcome of interest will be tumor recurrence at a minimum of 2 years follow-up. Study screening,
data extraction, and quality assessment will be done by two reviewers independently. Hazard ratios will be used to
measure the relationship between the potential prognostic factor and tumor recurrence. Meta-analyses will be
conducted with sufficiently homogeneous studies and separately with respect to study design, by using the
random-effects generic inverse variance model.
Discussion: Limitations and strengths will be discussed in our review, and the results will be put into context with
other studies in this field. Our results will help to guide evidence-based decision-making on patients with clinical
stage I seminoma, allowing a better adjustment of therapies with regard to the individual patient’s risk. Our findings
will furthermore help to formulate recommendations for future research.
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Keywords: Testicular cancer, Seminoma, Relapse, Rete testis invasion, Tumor diameter, Adjuvant therapy,
Surveillance, Systematic review, Prognostic factor
* Correspondence: frank.kunath@uk-erlangen.de
†Equal contributors
1Department of Urology, University Hospital of Erlangen, Erlangen, Germany
5UroEvidence@Deutsche Gesellschaft für Urologie, Berlin, Germany
Full list of author information is available at the end of the article
© 2015 Kunath et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kunath et al. Systematic Reviews  (2015) 4:182 
DOI 10.1186/s13643-015-0167-3
Background
Testicular cancer is primarily treated with inguinal
orchiectomy, that means the surgical removal of the
affected testis. Pathological examination reveals histology
of a seminoma in about 60 % of the cases, with an
increasing trend [1]. About 80 % of the diagnosed semi-
nomas are classified as clinical stage I. This stage is char-
acterized by the absence of metastases on radiologic
examination and by normal or normalized testis tumor
markers after orchiectomy. Data from large case series
show that despite normal radiologic and laboratory ex-
aminations on primary diagnosis, about 15–20 % of
stage I seminoma patients will develop a tumor relapse
in their further live [2]. Therefore, early additional (adju-
vant) therapies, namely adjuvant chemotherapy and ad-
juvant irradiation of the posterior abdominal wall, are
used for stage I patients because they are able to lower
the relapse risk to percentages <5 % [3, 4]. Another op-
tion for patients with stage I seminoma is a surveillance
strategy, which consists of a close follow-up of affected
patients rather than administering any active medical
intervention. Hence, surveillance, adjuvant radiation and
adjuvant chemotherapy are the three therapeutic options
for patients with clinical stage I seminoma.
Recent data suggest that radio- and chemotherapy har-
bor relevant long-term side effects, which often have
been neglected in the past [5, 6]. These long-term data
on chemo- or radiotherapy imply a more distinguished
point of view on adjuvant therapy regimens. The ideal
approach for stage I seminoma patients is to minimize
overtreatment without exposing the patient to an un-
necessary high risk of tumor relapse. In reality, this is
difficult to achieve, but prognostic factors at primary
diagnosis might have the potential to identify patients at
higher risk of tumor relapse. In clinical practice, they
can help to guide individual treatment and lead to re-
duced rates of overtreatment.
In 2002, Warde et al. published the results of a
retrospective study investigating the prognostic value
of histopathological findings in the primary tumor
specimen for relapse. They found a tumor diameter
greater than 4 cm and infiltration of the rete testis
being significantly associated with tumor relapse [7].
The same working group was unable to validate these
two risk factors in a prospective study [8]. Ensuing
prospective studies led to conflicting results regarding
the value of tumor diameter and rete testis infiltration
[9, 10]. Both candidate prognostic factors have been
used by some physicians in clinical decision making
for or against adjuvant therapy, especially in favor of
surveillance if both risk factors are absent. In contrast
to patients with stage I non-seminoma -where pT2
stage is an accepted risk factor-, the guidelines of the
European Association of Urology (EAU) and the
European Society of Medical Oncology (ESMO) do
not clearly recommend these prognostic factors for
the choice of treatment for stage I seminoma patients
[11, 12]. There were further efforts -sometimes only
in retrospective series or on a small number of pa-
tients- to identify other candidate prognostic factors
that are better suited to facilitate therapy guidance. A
number of molecular examinations on primary tumor
tissue or patient peripheral blood for different
markers have been done, but none of them has en-
tered the routine of clinical decision-making or even
the therapy guidelines.
Why it is important to do this review
The continuous discussion on different candidate prog-
nostic factors, of which some -despite lacking evidence-
have partly entered in clinical practice, leads to relevant
doubts and uncertainties in seminoma patients and the
doctors engaged in their treatment. Therefore, it seems
important to systematically review, evaluate and
summarize the existing information on prognostic fac-
tors in stage I seminoma to guide clinical decision mak-
ing on further treatment strategies and to inform and
facilitate future intervention research.
Method/design
Objectives
To synthesize the available evidence on the association
between primary tumor as well as clinical patient char-
acteristics as prognostic factors and cancer recurrence in
patients with clinical stage I seminoma, who received no
prior adjuvant therapy.
Review design
We will conduct a broad systematic review (as opposed
to a focused review that investigates evidence on only
one prognostic factor) to analyze what are the candidate
factors that predict cancer recurrence in clinical stage I
seminoma patients.
The conduction of systematic reviews of prognostic
factors is challenged by the selective reporting of prog-
nostic factor studies [13], eventually leading to false-
positive results, as well as by variations in methodology
and reporting of findings among primary studies [14].
To deal with these challenges, we will follow the work
done by the Prognostic Research Strategy (PROGRESS)
group that developed methods for prognosis research
studies [15]. Furthermore, we will follow the reporting
guidelines of Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) for systematic re-
views [16] and Reporting Recommendations for Tumor
Marker Prognostic Studies (REMARK) for (tumor marker)
prognostic studies [17].
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Types of studies
We will include prospective and retrospective longitudinal
observational studies investigating the prognosis of patients
with clinical stage I seminoma. We will also include inter-
vention studies, if they include a surveillance group and if
results are reported separately for this group. Studies are
eligible for inclusion if they report on patients diagnosed
with stage I tumor and provide data with a minimum
follow-up (median or mean) of 2 years. A minimum
follow-up of 2 years is required to exclude relevant uncer-
tainties of possible diagnostic factors, as about 30 % of
seminoma relapses are diagnosed in the second year of
follow-up and a 2-year follow-up covers at least about
75 % of all relapses [2]. Exploratory studies as well as con-
firmatory studies will be considered [18], if they provide
data on the association of clinical or pathohistological fac-
tors with tumor recurrence. Exploratory and confirmatory
studies will be treated differently in the analyses as they
provide different levels of evidence. We will also consider
studies published as abstracts; their limited significance will
be considered in the quality assessment process. Study in-
clusion will not be restricted by publication status. We will
exclude reviews, case reports, editorials and comments.
Types of participants
We will include patients with clinical stage I seminoma,
defined as the absence of metastasis shown with radio-
logical imaging and normal or normalized values for the
tumor marker Beta-human chorionic gonadotropin
(betaHCG). Eligible are patients of all ages, ethnicity and
comorbidity with a first time diagnosis of seminoma
stage I, who received no prior adjuvant treatment after
orchiectomy. We will exclude patients who received any
adjuvant therapy (e.g., chemo- or radiotherapy).
Types of prognostic factors
We will not focus at a specific prognostic factor but will
consider the wealth of any candidate clinical or patho-
logical prognostic factor reported in the literature. So
far, especially tumor size (>4 cm) and tumor infiltration
into rete testis have been reported to have a possible
prognostic value in predicting tumor recurrence in semi-
noma patients at clinical stage I [7]. If we identify any
other candidate prognostic factor during our review
process, we will also include it in our analyses.
Outcome measures
Our outcome of interest will be tumor recurrence during
the observed follow-up period, as the risk for tumor recur-
rence is the most important factor for decisions on adju-
vant therapy regimens. Tumor recurrence will be assessed
as reported by the authors, regardless of the mode of de-
tection (radiologic finding, histologic specimen, tumor
marker elevation) at the described time points.
Search methods for identification of studies
We will conduct a systematic review of the literature in
different electronic biomedical databases. Our search
will be complemented by additional handsearching of
meeting communications of the major conferences of
this topic. The searches were conducted in January 2015.
A final update search will be done before submitting the
final review draft for publication.
Electronic searches
Specific search strategies will be conducted for each of the
following databases: MEDLINE (from 1946 onwards), Web
of Science (from 1946 onwards), and the Cochrane Central
Register of Controlled Trials (CENTRAL) (from 1995 on-
wards). The search strategies are shown in Appendix 1,
Appendix 2, and Appendix 3. Search terms will combine
keywords and free text. No date or language restrictions
will be applied.
Searching other resources
We will handsearch the conference proceedings of
American Society of Clinical Oncology (ASCO), the An-
nual Meeting of the European Association of Urology
(EAU), and the American Urologic Association (AUA)
(American Urologic Association) from 2008 onwards.
Additionally, we will review the reference lists of the full
texts of potential relevant studies.
Data collection and analyses
Selection of studies
Articles will be selected for inclusion by title and ab-
stract review, performed by two authors independently.
The full text of the potentially relevant references will be
reviewed by the same authors independently, too. We
will provide a PRISMA study flow diagram with reasons
for exclusion at full text screen level. Discrepancies will
be resolved by discussion or by consulting a third review
author.
Data extraction and management
Data extraction will be done independently by two re-
view authors. Disagreement will be resolved through dis-
cussion or by consulting a third review author. The data
extraction form is inspired by the work of Moons et al.
and adapted for our purpose [19]. The following data
will be extracted: source of data (study design, study
dates, sample size, number of events per candidate prog-
nostic factor, exploratory/confirmatory approach, follow-
up length), participant characteristics (setting, inclusion
and exclusion criteria, recruitment method, sociodemo-
graphic characteristics, details of treatment received,
clinical tumor characteristics), candidate prognostic fac-
tors (number and type of prognostic factor, definition,
method and timing of measurement of candidate
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prognostic factors, all unadjusted (simple) and adjusted
(multivariable) associations reported between the
prognostic factor and the outcome, with details on any
adjustment factors that are used), outcomes (type of
outcome, definition, measurement and timing of outcome
assessment, time of outcome occurrence), and missing
data (number per patient/per candidate prognostic factor,
handling of missing data). The data extraction sheet will
be pilot-tested to ensure its performance.
We will classify included studies according to the au-
thors’ objectives, study design, definition of variables,
and analysis (exploratory versus confirmatory intent).
This information will be considered when interpreting
the strength of the available evidence.
We will not consider individual patient data as the
collection of such data is not feasible. Instead, we will
contact the authors of the original publication in case
of unclear or missing data.
If we identify several publications of the same study,
we will consider the most recent and comprehensive
one in the analysis.
All references will be managed and stored in EndNote
X7.
Assessment of risk of bias of included studies
Included studies will be critically appraised by two review
authors independently, using the Quality in Prognosis
Studies (QUIPS) tool, which is recommended by the
Cochrane Prognosis Method Group for prognostic factor
review questions. Discrepancies will be resolved through
discussion and reaching a consensus. If necessary, a third
author will be included. The QUIPS tool considers six do-
mains of assessment: study participation, study attrition,
prognostic factor measurement, outcome measurement,
study confounding, and statistical analysis and reporting
[20]. Results will be presented in a risk of bias table.
Data analysis and synthesis
Measures of association
Hazard ratios (HRs) will be used to measure the rela-
tionship between the potential prognostic factor and
tumor recurrence (time to event). We will extract all un-
adjusted and adjusted measures of association. An indir-
ect estimation method will be used to calculate log HRs
and their standard errors if they are not reported but ad-
equate univariate analyses are available [21]. Odds ratios
and relative risks will be used to estimate HRs as neces-
sary [22]. For consistency, we will re-calculate associa-
tions to be in the same direction, as necessary, with
associations above 1 indicating higher risk of relapse/
worse prognosis. Standard errors will be calculated from
confidence intervals and the individual study associa-
tions. Standard errors will be appropriately transformed
to their natural logarithms if necessary [23].
Unit of analysis
Data retrieved from the primary studies is analyzed at
the group level. We are aware that group or study level
analyses can lead to biased assessments and have some
limitations in revealing subset effects. But, in view of our
broad approach including a set of factors investigated
through a very long time span, we felt that an individual
patient level analysis is not feasible for the present issue.
Dealing with missing data
We will include all studies investigating the association
of clinical or pathological factors on tumor recurrence.
Studies with missing data or not significant results will
also be included. We will contact the corresponding au-
thor to request any important missing information or
clarify questions, if necessary.
Publication bias
We will investigate publication bias by creating funnel
plots for each meta-analysis containing at least ten stud-
ies. Publication bias will be assessed by visually examin-
ing the asymmetry of the funnel plot and by testing for
asymmetry at the 10 % level, using Egger’s test for HRs
and Peters’ test for odds ratios [24]. Furthermore, we
will contact experts in the field to identify unpublished
studies.
Meta-analysis
Meta-analyses will only be conducted if valid data are
available and data are sufficiently homogeneous for two
or more studies. Data synthesis will be done separately
with respect to differences in study design and study
quality by excluding studies with low and/or unclear risk
of bias.
In the meta-analyses, the random-effects generic in-
verse variance model will be used, which accounts for
any between-study heterogeneity in the prognostic ef-
fect. Such heterogeneity is common in prognostic factor
studies. Each meta-analysis will be summarized by the
pooled estimate (the average prognostic factor effect), its
95 % confidence interval, the estimate of Tau2 (between-
study variance), and a 95 % prediction interval for the
prognostic effect in a single population [25, 26].
For continuous prognostic factors, meta-analyses will
be conducted on the same scale. For dichotomous or
categorical prognostic factors, we will group studies with
similar cut points together to obtain meta-analysis re-
sults for each cut point as far as possible. To allow com-
bination of as much data as possible, dichotomous
associations will be computed from continuous and cat-
egorical measures of association from data in the study
reports or provided by the study authors on request. We
will explore the impact of data transformations using
sensitivity analyses.
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Assessment of heterogeneity
Forest plots as well as I2 and Tau2 will be used to assess
and quantify statistical heterogeneity across the studies
included in the meta-analyses (the estimate of between-
study variance). The thresholds for interpretation of I2
will be in accordance with the definitions presented in
the Cochrane Handbook for Systematic Reviews of
Interventions [27]:
– 0 to 40 % might not be important
– 30 % to 60 % may represent moderate heterogeneity
– 50 % to 90 % may represent substantial
heterogeneity
– 75 % to 100 % considerable heterogeneity
Clinical heterogeneity will be examined based on patient
characteristics, clinical and pathological characteristics,
and outcome measurement. Methodological heterogeneity
will be examined based on study design and potential
biases.
If it is not appropriate to combine the results in a
meta-analysis (due to a small number of studies and/or
if the interpretation of results would be difficult due to
heterogeneity), they will be presented qualitatively by
considering the strength and consistency of results.
Therefore, the following schema will be used:
Strength of association will be defined based on effect
size as weak (HR <1.5), moderate (HR 1.5–2.9), or
strong (HR ≥3). Consistency of findings will be assessed
using the following schema:
– Strong evidence of effect: Consistent findings
(defined as >75 % of studies showing the same
direction of effect) in multiple low risk of bias
studies
– Moderate evidence of effect: Consistent findings in
multiple high risk of bias and/or one study with low
risk of bias
– Limited evidence of effect: One study available
– Conflicting evidence: Inconsistent findings across
studies
– No evidence: No association between patient
expectations and the outcome of interest
Sensitivity analyses
The robustness of results will be tested by sensitivity
analyses.
Additional analyses will include the following
comparisons:
– Exploratory versus confirmatory study results
– Retrospective versus prospective designs
– Categorized versus continuous data of the same
factor
– Significant associations versus non-significant
associations
– Adjusted versus non adjusted analyses
– Follow-up time (2 years, 3 years, 5 years, 10 years)
Data synthesis will be performed using Review Manager
5.3 provided by The Cochrane Collaboration [28].
Statistical methods not available in the Review Manager
will be done using the statistical software R with the
“meta” package [29, 30].
Discussion
The value of prognostic markers for a tumor relapse in
patients with clinically organ-confined stage I seminoma
is discussed controversially in the medical literature.
There is only little evidence from primary research, mak-
ing decisions on adjuvant treatment for these patients
difficult. Therefore, we will conduct a broad systematic
review to identify prognostic factors that might be able
to predict cancer recurrence in patients with clinical
stage I seminoma. Current limitations of prognostic fac-
tor research is challenged by publication bias, reporting
bias, poor statistical analyses, and inadequate reporting
of methods and findings of primary studies. But within
the increasing body of evidence, it becomes important to
summarize the available information and thereby over-
coming the limited validity of primary studies.
Systematic reviews of prognostic factors also provide
several challenges, as they have been criticized for their
limitation in providing relevant information due to
missing quality appraisal of primary studies and poor
adherence to standardized methodology and reporting.
To overcome these challenges, we will follow the rec-
ommendations of conducting systematic reviews of
prognostic studies, provided by the Cochrane Method
Group of Prognosis Reviews and the PRISMA and
REMARK reporting guidelines for systematic reviews
and prognostic studies. Study appraisal for prognostic
reviews is more difficult than for interventional reviews
because there has been less research and funding in this
field so far. We will use the QUIPS tool, recently described
by Hayden et al. and recommended by the Cochrane
Prognosis Methods Group [20].
Our results of the aggregation and critical appraisal
of the available evidence will help to guide evidence-
based treatment decision-making on patients with
clinical stage I seminoma, allowing proper adjustment
of therapies with regard to the individual patient’s
risk. The discussion part of our study will address the
limitations and strengths of this study. Our findings
will be compared to results of other studies in this
field. Our findings will furthermore help to formulate
recommendations for future research, and clinical im-
plications will be discussed.






ASCO: American Society of Clinical Oncology; AUA: American Urologic
Association; CENTRAL: Cochrane Central Register of Controlled Trials;
DGU: Deutsche Gesellschaft für Urologie; EAU: European Association of
Urology; ESMO: European Society of Medical Oncology; HR: hazard ratio;
OR: odds ratio; PRISMA: Preferred Reporting Items for Systematic Reviews
and Meta-analyses; PROGRESS: Prognostic Research Strategy; QUIPS: Quality
in Prognosis Studies; REMARK: Reporting Recommendations for Tumor
Marker Prognostic Studies.
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